Soaring Demand Set to Propel Congenital Heart Disease (CHD) Market to $7.05 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Congenital Heart Disease (CHD) Market Through 2025?
The market for congenital heart disease (CHD) has witnessed a significant expansion in the past few years. Projected to amplify from $4.42 billion in 2024 to $4.87 billion in 2025, the market expects a compound annual growth rate (CAGR) of 10.1%. The historical period of market growth owes to the increased incidence of risk factors like obesity and smoking, advancements in diagnostic technology, an increase in the elderly population, more effective awareness campaigns, improved reimbursement policies and an ascension in research and development investments.

What's the Projected Size of the Global Congenital Heart Disease (CHD) Market by 2029?
The market size for congenital heart disease (CHD) is projected to experience substantial growth in the coming years, reaching $7.05 billion by 2029 with a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this expansion during the forecast period include increased access to healthcare services in evolving regions, ongoing advancements in cardiac imaging technologies, heightened public awareness campaigns for early detection and treatment, the global increase in healthcare spending, and the progression of personalized medicine. Key trends predicted to continue into the forecast period encompass the use of minimally invasive surgical methods, incorporating telemedicine for patient monitoring and remote consultations, growing needs for individualized treatment plans, creation of cutting-edge implantable devices with improved performance and lifespan, and the inclusion of artificial intelligence and machine learning in diagnostic and treatment procedures.

View the full report here:
https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Top Growth Drivers in the Congenital Heart Disease (CHD) Industry: What's Accelerating the Market?
The projected rise in mothers dealing with diabetes is likely to spur the expansion of the congenital heart disease (CHD) market. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is a form of diabetes that emerges during pregnancy in females who weren't previously diabetic. This condition emerges as a result of lifestyle changes like lack of physical activity and unhealthy eating habits and is further fueled by the growing obesity figures among women of reproductive age. High blood sugar levels in mothers due to diabetes can influence fetal heart development, resulting in congenital heart disease (CHD) amongst newborns. The elevated glucose levels interfere with the regular development of the infant's heart, enhancing the probability of CHD. As an illustration, as per the UK's National Health Service in October 2023, unwelcome pregnancy outcomes for women diagnosed with type 2 diabetes in 2021 were at 4.9% which then heightened to 6.6% in 2022. Hence, the rise in incidents of maternal diabetes forms a significant factor powering the growth of the congenital heart disease (CHD) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

What Trends Will Shape the Congenital Heart Disease (CHD) Market Through 2029 and Beyond?
In the congenital heart disease market, leading firms are focusing on the development of non-surgical heart valves to enhance both the results for patients and their quality of life. Transcatheter or non-surgical heart valves, which are essentially medical devices, offer treatment for heart valve conditions without necessitating conventional open-heart surgery. For example, Medtronic, an American medical technology firm, relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System in February 2023. This innovative system, which only involves minimal invasiveness, serves as an alternative to open-heart surgeries for patients dealing with congenital heart disease, particularly those who have native or surgically repaired anomalies in their right ventricular outflow tract (RVOT). Notably, this system is the first valve approved by the FDA specifically for the right side, bringing a non-surgical resolution for patients with severe pulmonary valve regurgitation. After a voluntary recall, the Harmony TPV System, which had initially received FDA approval in 2021, was reintroduced, highlighting Medtronic's dedication to producing advanced solutions for congenital heart disease patients.

What Are the Main Segments in the Congenital Heart Disease (CHD) Market?
The congenital heart disease (CHD) market covered in this report is segmented -

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types
2) By Diagnosis: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis
3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications
4) By Age Group: Infants, Children, Adolescents, Adults
5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:
1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation
2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)
3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus
4) By Other Types: Single Ventricle Defects, Ebstein's Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp

Which Top Companies are Driving Growth in the Congenital Heart Disease (CHD) Market?
Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

Which Regions Will Dominate the Congenital Heart Disease (CHD) Market Through 2029?
North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15545

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.